


DRUG EFFECTS ON LABORATORY TEST RESULTS

Analytical Interferences and
Pharmacological Effects

Gérard Siest / Marie-Madeleine Galteau



DRUG EFFECTS ON LABORATORY TEST RESULTS

一九九〇年四月八日

**Analytical Interferences and
Pharmacological Effects**

Gérard Siest / Marie-Madeline Galteau



PSG Publishing Company, Inc.
Littleton, Massachusetts



18 4

Library of Congress Cataloging-in-Publication Data

Examens de laboratoire et médicaments. English.
Drug effects on laboratory test results.

Translation of: Examens de laboratoire et médicaments.

1. Chemistry, Clinical. 2. Drug interactions.
3. Drugs—Side effects. I. Siest, G. II. Galteau, M.-M. (Marie-Madeleine) III. Title. [DNLM:
 1. Blood Chemical Analysis. 2. Diagnosis, Laboratory.
 3. Diagnostic Errors. 4. Drugs—adverse effects.
 5. Urine—analysis QY 450 E96]

RB40.E9313 1987 616.07'56 87-7354

ISBN 0-88416-721-6

Editing of this book in English was made possible by the assistance of the Commission of European Communities and the Editorial Group of the Community.

Copyright © 1988 by PSG PUBLISHING COMPANY, INC.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage or retrieval system, without permission in writing from the publisher.

Printed in the United States of America.

International Standard Book Number: 0-88416-721-6

Library of Congress Catalog Card Number: 87-7354

Last digit is the print number: 9 8 7 6 5 4 3 2 1

CONTRIBUTORS

Y. Artur, Ph.D. Clinical Biochemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

M. Balland, M.Sc. Clinical Chemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

N. Chatourel, Computer Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

A. Cloarec, Ph.D. Clinical Biochemist, UPSA Laboratories, Rueil Malmaison, France.

I. Cuvelier, Ph.D. Clinical Biochemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

J. Delattre, Ph.D. Clinical Biochemist, Laboratory Department, Faculty of Pharmaceutical and Biological Sciences, Paris, France.

P. Delwaide, M.D., Laboratory of Medical Chemistry, University of Liège, Liège, Belgique.

M.C. Diemert, Ph.D. Clinical Biochemist, Biochemical Department, Hospital of Salpêtrière, Paris, France.

A.Y. Floc'h, Ph.D. Head, Computer Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

J. Frei, Ph.D. Director, Laboratory Central of Clinical Chemistry, Hospital Center University, Lausanne, Suisse.

R. Galimany, Ph.D. Head, Health Department, Hospital of Badalona, Barcelone, Espagne.

A. Galli, Ph.D. Head, Biochemical Department, Hospital of Salpêtrière, Paris, France.

M.M. Galteau, Ph.D. Director, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, and Professor of Clinical Chemistry, University of Nancy, Nancy, France.

D. Gouy, Ph.D. Clinical Biochemist, Research Center, Clin Midy, Montpellier, France.

J.F. Guelfi, Ph.D., National Veterinary School, Toulouse, France.

J. Henny, Ph.D. Director, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

B. Herbeth, M.Sc. Clinical Biochemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

J. Hitz, Ph.D. Clinical Biochemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

M.C. Jaudon, Ph.D. Clinical Biochemist, Biochemical Department, Hospital of Salpêtrière, Paris, France.

P. Jouanel, M.D. Clinical Biochemist, Biochemical Medical Department, Hôtel Dieu, Clermont-Ferrand, France.

L. Lepage, Ph.D. Clinical Biochemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

F. Schiele, Ph.D. Director, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

G. Siest, Ph.D. Head, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, and Professor of Biochemical Pharmacology, University of Nancy, Nancy, France.

J. Steinmetz, Ph.D. Clinical Biochemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

P. Tarallo, M.Sc. Clinical Chemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

Y. Thuillier, Ph.D. Clinical Biochemist, Biochemical Department, Hospital of Salpêtrière, Paris, France.

F. Trivin, Ph.D. Clinical Biochemist, Biochemical Department, Hospital Saint-Joseph, Paris, France.

A. Vassault, Ph.D. Biochimie A Laboratory, Hospital Necker-Enfants Malades, Paris, France.

M. Vincent-Viry, M.Sc. Clinical Chemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

D.S. Young, M.B., Ph.D., Head, Division of Laboratory Medicine, Department of Pathology Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, USA.

A. Zhiri, Ph.D. Clinical Biochemist, Laboratory Department, Center for Preventive Medicine, Vandoeuvre-les-Nancy, France.

DRUG EFFECTS ON LABORATORY TEST RESULTS.
ANALYTICAL INTERFERENCES AND PHARMACOLOGICAL EFFECTS

Contents



<u>FOREWORD</u>	1	2.5.2. System for classification of drugs.....	46
<u>LABORATORY TESTS AND DRUGS</u>	3	2.5.3. Possible uses of a "drug" database.....	48
1. EFFECTS OF DRUGS ON LABORATORY TESTS.....	3	2.5.3.1. To investigate drug consumption.....	48
1.1. Analytical interference.....	6	2.5.3.2. To investigate pharmacological effects of drugs on laboratory tests.....	48
1.2. Biological effects.....	10	2.6. Investigation of analytical interferences.....	49
1.2.1. Knowing and controlling non-drug sources of variation.....	11	2.6.1. Products and laboratory tests to be investigated.....	49
1.2.2. Knowing the information about the drug.....	12	2.6.2. Analytical procedure.....	50
1.2.3. Knowing and controlling information about the subjects.....	12	2.6.2.1. Dissolving the drug and/or its metabolite.....	50
1.2.4. Information on the biological constituents measured.....	12	2.6.2.2. Choice of biological specimens.....	50
1.2.5. Analysis and use of the data.....	13	2.6.2.3. Demonstration of interference.....	50
1.2.6. Mechanisms involved.....	13	2.6.2.4. Quantitative measurement of interference.....	50
2. USE OF LABORATORY TESTS DURING DRUG DEVELOPMENT AND FOR MONITORING THERAPY.....	14	<u>ALBUMIN</u>	52
2.1. Choosing laboratory tests for toxicity trials in animals.....	15	1. METABOLIC BACKGROUND.....	52
2.2. Choosing and using laboratory tests during clinical trials.....	17	2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	52
2.3. Laboratory tests that are evidence of enzyme induction.....	22	3. ANALYTICAL INTERFERENCES.....	55
2.3.1. Proteins and plasma enzymes.....	22	3.1. Colorimetric methods: BCG and HABA.....	55
2.3.2. Enzymes of circulating blood cells.....	25	3.2. Protein electrophoresis.....	63
2.3.3. Endogenous metabolites changes by enzyme induction.....	25	4. PHARMACOLOGICAL EFFECTS.....	64
2.3.4. Measurement of drugs or of their metabolites.....	27	4.1. Drugs with a hemodynamic effect.....	64
2.4. Pharmacogenetics.....	28	4.2. Oral contraceptives, estrogens.....	64
2.4.1. Introduction.....	28	4.3. Anabolic drugs and testosterone.....	64
2.4.2. Action of drugs in subjects with hereditary illnesses.....	29	4.4. Ascorbic acid.....	65
2.4.3. Enzyme deficiencies revealed by the administration of a drug.....	29	4.5. Antiepileptic drugs.....	65
2.5. Use of laboratory tests to monitor the taking of drugs.....	31	4.6. Antihypertensive drugs.....	65
2.5.1. Monitoring the effectiveness of drugs and adjustment of the dosage.....	31	4.7. Miscellaneous.....	65
2.5.2. Monitoring secondary effects of treatments.....	32	4.8. Drugs with no effect on albumin concentration.....	65
2.5.3. Demonstration of a threshold toxicity or of an overdose.....	33	5. TOXIC EFFECTS.....	66
2.5.4. Risk evaluation.....	33	<u>ALKALINE PHOSPHATASES</u>	67
2.5.5. The particular problem of immunological and immunological reactions.....	35	1. INTRODUCTION.....	67
<u>CONCLUSIONS</u>	35	2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	68
<u>GATHERING INFORMATION AND CONTROLLING ITS QUALITY</u>	37	3. ANALYTICAL INTERFERENCES.....	70
1. THE CENTRE FOR PREVENTIVE MEDICINE.....	38	3.1. Analytical increases of AP activity.....	71
2. GATHERING THE DATA.....	38	3.2. Analytical decreases of AP activity.....	73
2.1. Function tests.....	39	3.3. No analytical interference.....	74
2.2. Questionnaire.....	39	4. PHARMACOLOGICAL EFFECTS.....	79
2.2.1. Questionnaire on life style.....	39	4.1. Desired effects.....	79
2.2.2. Questionnaire on health related issues.....	39	4.2. Undesirable effects.....	79
2.3. Laboratory tests.....	39	4.2.1. Analgesics, antipyretics and nonsteroidal anti-inflammatory drugs (NSAID).....	80
2.3.1. Blood specimens.....	41	4.2.2. Antibiotics.....	81
2.3.2. Laboratory tests: production of the data.....	42	4.2.3. Antidepressant agents.....	82
2.3.3. Quality control on the data.....	44	4.2.4. Anti-infectious agents.....	83
2.4. Storing the data.....	44	4.2.5. Antiangina, coronary vasodilator, and anti-arrhythmic agents.....	84
2.5. Drug file.....	44	4.2.6. Antiepileptic drugs.....	84
2.5.1. Gathering of information: codification of drugs.....	44	4.2.7. Lipid-lowering drugs.....	85
		4.2.8. Oral contraceptives.....	86
		4.2.9. Antihypertensive drugs.....	86
		4.2.10. Drugs used to treat tuberculosis.....	86
		4.2.11. Anti-cancer agents.....	87
		4.2.12. Diuretics.....	87
		4.2.13. Anesthetics.....	87
		4.2.14. Platelet aggregation inhibitors.....	87
		4.2.15. Anticoagulants.....	88
		4.2.16. Anti-gout agents.....	88
		4.2.17. Tranquillizers.....	88

4.2.18. Neuroleptics.....	88
4.2.19. Vitamins.....	89
4.2.20. Hormones.....	89
4.2.21. Miscellaneous.....	89
5. CONCLUSION.....	90

ASPARTATE AMINOTRANSFERASE and ALANINE AMINOTRANSFERASE.....

INTRODUCTION.....	91
1. PLASMA ASPARTATE AMINOTRANSFERASE (P-AST).....	92
1.1. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	92
1.2. ANALYTICAL INTERFERENCES.....	95
1.2.1. Analytical increases of AST activity.....	95
1.2.2. Analytical decreases of AST activity.....	96
1.2.3. No analytical interference.....	96
1.3. PHARMACOLOGICAL EFFECTS.....	103
1.3.1. General comments.....	103
1.3.2. Analgesics, antipyretics, and nonsteroidal anti-inflammatory drugs (NSAID).....	106
1.3.3. Anesthetics.....	107
1.3.4. Anticoagulants.....	108
1.3.5. Antibiotics and anti-infectious agents.....	108
1.3.6. Antidepressant agents.....	108
1.3.7. Antiepileptic drugs.....	109
1.3.8. Agents acting on the cardiovascular system.....	109
1.3.9. Antihypertensive drugs.....	110
1.3.10. Oral contraceptives.....	110
1.3.11. Diuretics.....	110
1.3.12. Neuroleptics.....	110
1.3.13. Lipid-lowering drugs.....	110
1.3.14. Drugs used to treat tuberculosis.....	111
1.3.15. Miscellaneous.....	111
11. PLASMA ALANINE AMINOTRANSFERASE (P-ALT).....	112
11.1. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	112
11.2. ANALYTICAL INTERFERENCES.....	114
11.3. PHARMACOLOGICAL EFFECTS.....	121
11.3.1. General comments.....	121
11.3.2. Analgesics, antipyretics and anti-inflammatory agents.....	121
11.3.3. Anesthetics.....	121
11.3.4. Anticoagulants.....	122
11.3.5. Antibiotics and anti-infectious agents.....	122
11.3.6. Antidepressant agents.....	123
11.3.7. Agents acting on the cardiovascular system.....	124
11.3.8. Drugs used to treat tuberculosis.....	125
11.3.9. Antiepileptic drugs.....	126
11.3.10. Diuretics, antihypertensive drugs.....	127
11.3.11. Oral contraceptives.....	127
11.3.12. Laxatives.....	128
11.3.13. Neuroleptics.....	128
11.3.14. Anti-cancer drugs.....	128
CONCLUSION.....	128

TOTAL BILIRUBIN.....

1. METABOLIC BACKGROUND.....	131
2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	132
3. ANALYTICAL INTERFERENCES.....	134
3.1. Methods of quantitative analysis.....	134
3.1.1. Diazotization reaction (Jendrassik and Grof).....	134
3.1.2. Spectrophotometric methods.....	135

3.2. Main analytical interferences.....	135
3.2.1. Colored reaction.....	135
3.2.2. Spectrophotometric methods.....	136
3.3. No analytical interference.....	136
4. PHARMACOLOGICAL EFFECTS.....	142
4.1. Drugs causing hypobillirubinemia.....	142
4.1.1. Inducers.....	142
4.1.2. Cholericotics.....	143
4.1.3. Salicylates.....	143
4.2. Drugs increasing bilirubin.....	143
4.2.1. Increase in the production of unconjugated bilirubin: hemolysis.....	144
4.2.2. Intrahepatic effect: hepatotoxicity.....	144
4.2.2.1. By cell destruction.....	144
. Anesthetics.....	144
. Anti-inflammatory drugs.....	144
. Anti-infectious agents.....	145
. Antiepileptic drugs.....	145
. Drugs used to treat tuberculosis.....	146
4.2.2.2. Blocking of glucuronide conjugation.....	146
4.2.2.3. Blocking of biliary excretion: cholestasis.....	146
4.2.2.4. Reduction in hepatic uptake.....	146
4.2.3. Immunoallergy.....	147
4.2.4. Unknown mechanism.....	147

TOTAL CALCIUM.....

1. METABOLIC BACKGROUND.....	148
2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	149
3. ANALYTICAL INTERFERENCES.....	152
3.1. Methods used.....	152
3.2. Analytical increases of calcium.....	153
3.3. Analytical decreases of calcium.....	153
3.4. No analytical interference.....	153
4. PHARMACOLOGICAL EFFECTS.....	159
4.1. Diphosphonates.....	159
4.2. Vitamin D.....	160
4.3. Antiepileptic drugs.....	161
4.4. Oral contraceptives.....	162
4.5. Antihypertensive drugs.....	162
4.6. Diuretics.....	162
4.7. Antiarrhythmics.....	162
4.8. Antibiotics.....	163
4.9. Tranquillizers.....	163
4.10. Anti-inflammatory agents.....	163
4.11. Hypoglycemic agents.....	163
4.12. Anti-gout drugs.....	163
4.13. Respiratory therapy.....	164
4.14. Thyroid hormones.....	164
4.15. Cardiotonic agents.....	164
4.16. Miscellaneous.....	164

TOTAL CHOLESTEROL.....

1. METABOLIC BACKGROUND.....	165
2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	166
3. ANALYTICAL INTERFERENCES.....	168
3.1. Analytical methods.....	168
3.2. Analytical interferences: chemical methods.....	169
3.3. Analytical interferences: enzymatic methods.....	175
4. PHARMACOLOGICAL EFFECTS.....	176
4.1. Lipid-lowering drugs.....	176
4.1.1. Phenoxisobutyric acid derivatives.....	176
4.1.2. Nicotinic acid and its derivatives.....	177

4.1.3. Sulfur-containing derivatives.....	177	4.1. Antibiotics.....	216
4.1.4. Drugs which inhibit intestinal reabsorption of cholesterol and bile acids.	177	4.2. Anti-gout agents.....	217
4.2. Hypoglycemic agents.....	177	4.3. Psychotropic drugs.....	217
4.3. Antihypertensive drugs.....	179	4.4. H ₂ -receptor antagonists.....	218
4.4. Oral contraceptives.....	181	4.5. Analgesics and anti-inflammatory drugs.....	219
4.5. Hormones.....	182	4.6. Cardiac drugs.....	219
4.6. Antiepileptic drugs.....	183	4.6.1. Antiangina drugs.....	219
4.7. Vitamins.....	183	4.6.2. Antihypertensive drugs.....	220
4.8. Antibiotics.....	184	4.7. Diuretics.....	220
4.9. Miscellaneous.....	184	4.8. Sulfonamides.....	220
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL	185	4.9. Hormones.....	221
1. METABOLIC BACKGROUND.....	185	4.10. Cytostatic drugs.....	222
2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	186	4.11. Miscellaneous.....	222
3. ANALYTICAL INTERFERENCES.....	188	GAMMA-GLUTAMYLTRANSFERASE	224
4. PHARMACOLOGICAL EFFECTS.....	189	1. METABOLIC BACKGROUND.....	224
4.1. Lipid-lowering drugs.....	189	2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	225
4.2. Antihypertensive drugs.....	191	2.1. Measurement of serum GGT activity.....	225
4.3. Oral contraceptives.....	192	2.2. Reference limits.....	225
4.4. Antiepileptic drugs.....	196	2.3. Preanalytical variations.....	227
4.5. Miscellaneous.....	196	2.4. Physiological variations.....	227
CREATININE	198	2.5. Pathological variations.....	228
1. METABOLIC BACKGROUND.....	198	3. ANALYTICAL INTERFERENCES.....	228
2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	199	3.1. Drugs interfering in the measurement of plasma GGT activity.....	228
3. ANALYTICAL INTERFERENCES.....	200	3.2. No analytical interference.....	229
3.1. Analytical methods.....	200	4. PHARMACOLOGICAL EFFECTS.....	229
3.1.1. Method of Jaffé.....	200	4.1. Mechanisms responsible for the variations of plasma GGT activity.....	229
3.1.2. Improvements to the Jaffé reaction.....	201	4.2. Pharmacological effects on the measurement of plasma GGT activity.....	230
3.1.3. Enzymatic technique.....	201	4.2.1. Antiepileptic drugs.....	230
3.1.4. Other methods.....	201	4.2.2. Antidepressant agents.....	232
3.2. Analytical interferences on the various methods.....	201	4.2.3. Oral contraceptives.....	232
3.2.1. End-point Jaffé reaction.....	202	4.2.4. Lipid-lowering drugs.....	233
3.2.2. Kinetic Jaffé reaction.....	203	4.2.5. Anticoagulants.....	233
3.2.3. Other methods.....	203	4.2.6. Anti-gout drugs.....	234
4. PHARMACOLOGICAL EFFECTS.....	207	4.2.7. Antihypertensive drugs.....	234
4.1. Decrease in creatinine concentration.....	207	4.2.8. Antipyretics.....	234
4.2. Increase in creatinine concentration.....	208	4.2.9. Antianginal drugs.....	235
4.2.1. Antibiotics.....	208	4.2.10. Antiarrhythmic drugs.....	235
4.2.2. Analgesics-antipyretics.....	208	4.2.11. Anti-cancer drugs.....	235
4.2.3. Anti-inflammatory drugs.....	208	4.2.12. Anti-infectious and anti-parasitic drugs.....	235
4.2.4. Diuretics.....	209	4.2.13. Drugs used to treat tuberculosis.....	236
4.2.5. Antihypertensive drugs.....	209	4.2.14. Hypoglycemic agents.....	236
4.2.6. Miscellaneous.....	210	4.2.15. Hypnotic drugs.....	236
ERYTHROCYTES AND HEMOGLOBIN	211	4.2.16. Thrombolytic drugs.....	237
1. INTRODUCTION.....	211	4.2.17. Tranquillizers.....	237
1.1. Direct myelotoxicity.....	211	4.2.18. Vasodilators and vasoconstrictors.....	237
1.2. Immunoallergic reactions.....	212	4.2.19. Miscellaneous.....	237
1.2.1. Hapten-like reactions.....	212	4.2.20. Drugs without effect on GGT activity.....	237
1.2.2. Formation of immune complexes.....	212	4.3. Effects of alcohol intake on the measurement of serum GGT activity.....	237
1.2.3. Formation of autoantibodies.....	212	GLUCOSE	241
1.2.4. Non-specific forms.....	213	1. METABOLIC BACKGROUND.....	241
1.3. Dyserythropoiesis.....	213	2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	241
1.4. Erythrocytosis.....	213	3. ANALYTICAL METHODS.....	244
2. REFERENCE LIMITS, AND PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	214	3.1. Enzymatic methods.....	244
3. ANALYTICAL INTERFERENCES.....	215	3.1.1. Methods using glucose oxidase (GOD).....	244
4. PHARMACOLOGICAL EFFECTS.....	216	3.1.2. Methods using hexokinase and glucose-6-phosphate dehydrogenase (G6PD).....	245
		3.1.3. Methods using glucose dehydrogenase (GDH).....	246

3.2. Chemical methods.....	247	4.1.2.3. Anticoagulants.....	295
3.2.1. Methods based on the reducing action of glucose on various metallic salts.....	247	4.1.2.4. Vitamins.....	296
3.2.2. Methods based on glucose Furfuralization.....	247	4.2. Drugs increasing LD activity.....	296
4. ANALYTICAL INTERFERENCES.....	247	4.2.1. Evaluation according to class of drug.....	296
4.1. Main sources of analytical interferences.....	248	4.2.1.1. Antiepileptic drugs.....	296
4.1.1. Methods using glucose oxidase, peroxidase, and a chromogen.....	253	4.2.1.2. Antihypertensive drugs.....	297
4.1.2. Methods using glucose oxidase and an electrochemical technique.....	254	4.2.1.3. Lipid-lowering drugs.....	297
4.1.3. Method using hexokinase/glucose-6-phosphate dehydrogenase.....	254	4.2.2. Administration of only one drug.....	297
4.1.4. Method using glucose dehydrogenase.....	254	4.2.2.1. Analgesics.....	297
4.1.5. Methods using o-toluidine.....	254	4.2.2.2. Antidepressant agents.....	298
4.1.6. Methods using ferricyanide or neocuproine.....	255	4.2.2.3. Anti-inflammatory agents.....	298
4.2. No analytical interference.....	255	4.2.2.4. Drugs used to treat tuberculosis.....	299
5. PHARMACOLOGICAL EFFECTS.....	264	4.2.3. Drugs used in combination.....	299
5.1. Drugs with hypoglycemic action.....	264	4.2.3.1. Anesthetics.....	299
5.1.1. Hypoglycemic agents.....	264	4.2.3.2. Antiepileptic drugs.....	299
5.1.1.1. Insulin.....	265	4.2.3.3. Oral contraceptives.....	300
5.1.1.2. Sulfonylurea compounds.....	265	4.2.4. Toxic effects increasing LD activity.....	300
5.1.1.3. Biguanides.....	265	4.3. Drugs decreasing LD activity.....	301
5.1.1.4. Glymidine.....	265	4.3.1. Evaluation according to class of drug.....	301
5.1.2. Other drugs that can cause a fall in blood glucose.....	266	4.3.2. Drugs used in combination.....	302
5.2. Drugs with hyperglycemic action.....	266		
5.2.1. Glucagon.....	266	TOTAL LEUKOCYTE COUNT.....	307
5.2.2. Diazoxide.....	267	1. INTRODUCTION.....	307
5.2.3. Thiazide diuretics.....	267	1.1. Adverse reaction due to direct myelotoxicity.....	309
5.2.4. Phenytoin.....	267	1.2. Immuno-allergic reactions affecting stem cells or circulating cells.....	311
5.2.5. Glucocorticoids.....	267	1.3. Increased leukocyte production.....	312
5.2.6. Epinephrine.....	268	1.4. Neutrophil compartment modification.....	312
5.2.7. Antihypertensive drugs.....	268	2. REFERENCE LIMITS, AND PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	314
5.2.8. Salbutamol.....	268	2.1. Analytical variations.....	314
5.2.9. Nifedipine.....	268	2.2. Method used to establish reference values.....	315
5.2.10. Diazepam.....	268	2.3. Other methods of counting white blood cells.....	315
		2.4. Reference limits, physiological, and patholo- gical variations.....	315
LACTATE DEHYDROGENASE.....	269	3. ANALYTICAL INTERFERENCES.....	317
1. METABOLIC BACKGROUND.....	269	4. PHARMACOLOGICAL EFFECTS.....	318
2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	270	4.1. Antidepressants, antiepileptics, and neuro- leptic drugs.....	318
3. ANALYTICAL INTERFERENCES.....	273	4.2. Anti-inflammatory, analgesic, and antipyretic drugs.....	320
3.1. Principal methods of measurement.....	276	4.3. Cardiovascular agents, antihistamines, and bronchodilators.....	321
3.2. Drugs that do not cause analytical interfe- rences in estimation of LD activity.....	277	4.4. Antibiotics.....	322
3.2.1. Colorimetric methods.....	277	4.5. Sulfamides and sulfonamides.....	323
3.2.2. UV spectrophotometric methods.....	278	4.6. Antiproliferative agents.....	324
3.2.2.1. Reaction proceeding in the direction: lactate to pyruvate.....	278	4.7. Anti-infectious, antimalarial, antiprotozoal, and anthelmintic drugs.....	325
3.2.2.2. Reaction proceeding in the direction: pyruvate to lactate.....	279	4.8. Immunostimulating agents.....	326
3.2.3. Unspecified methodology.....	280	4.9. Antihypertensive drugs.....	327
3.3. Drugs that cause analytical interferences in measurement of LD activity.....	285	4.10. Anesthetics.....	327
3.3.1. Colorimetric methods.....	286	4.11. Drugs for the treatment of hyperuricemia.....	328
3.3.2. UV spectrophotometric methods.....	287	4.12. Antithyroid drugs.....	328
3.3.2.1. Reaction proceeding in the direction: lactate to pyruvate.....	287	4.13. Diuretics.....	328
3.3.2.2. Reaction proceeding in the direction: pyruvate to lactate.....	289	4.14. Oral contraceptives.....	328
4. PHARMACOLOGICAL EFFECTS.....	291	4.15. Miscellaneous.....	329
4.1. Drugs that have no pharmacological effect on LD activity.....	294		
4.1.1. Evaluation according to class of drug.....	294	PHOSPHATES.....	330
4.1.2. Administration of only one drug.....	295	1. METABOLIC BACKGROUND.....	330
4.1.2.1. Anesthetics.....	295	2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	331
4.1.2.2. Antibiotics.....	295	3. ANALYTICAL INTERFERENCES.....	334
		3.1. Analytical increases of phosphates.....	334
		3.2. Analytical decreases of phosphates.....	335
		3.3. No analytical interference.....	335

4. PHARMACOLOGICAL EFFECTS.....	339	4.10. Bronchodilator drugs.....	372
4.1. Diuretics.....	339	4.11. Anti-inflammatory drugs.....	372
4.2. Antihypertensive drugs.....	340	4.12. Vitamins.....	373
4.3. Antiasthmatic agents.....	340	4.13. Laxatives.....	373
4.4. Oral contraceptives.....	340	4.14. Miscellaneous.....	373
4.5. Estrogens.....	340		
4.6. Antiepileptic drugs.....	341	TOTAL PROTEINS.....	375
4.7. Barbiturates.....	341	1. METABOLIC BACKGROUND.....	375
4.8. Tranquillizers.....	341	2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	375
4.9. Neuroleptics.....	341	3. ANALYTICAL INTERFERENCES.....	377
4.10. Lipid-lowering drugs.....	341	3.1. Biuret method.....	378
4.11. Vitamins.....	342	3.2. Refractometry.....	384
4.12. Glucose.....	342	3.3. Folin-Ciocalteu and Lowry methods.....	385
4.13. Miscellaneous.....	342	4. PHARMACOLOGICAL EFFECTS.....	389
		4.1. Drugs with hemodynamic effect.....	389
PLATELETS.....	344	4.2. Oral contraceptives and estrogens.....	389
1. INTRODUCTION.....	344	4.3. Anabolic steroids and testosterone.....	390
1.1. Thrombocytosis.....	344	4.4. Antiepileptic drugs.....	390
1.2. Thrombocytopenia.....	344	4.5. Miscellaneous.....	390
1.3. Changes in platelet function.....	346	5. TOXIC EFFECTS.....	390
2. REFERENCE LIMITS, AND ANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	346		
2.1. Analytical variations and the method used to establish reference values.....	346	SODIUM.....	391
2.2. Reference limits and physiopathological variations.....	347	1. METABOLIC BACKGROUND.....	391
3. PHARMACOLOGICAL EFFECTS.....	349	2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	392
3.1. Antibiotics, drugs used to treat tuberculosis.....	349	3. ANALYTICAL INTERFERENCES.....	395
3.2. Analgesics, anti-inflammatory and antipyretic drugs.....	352	3.1. Analytical increases of sodium.....	395
3.3. Antiepileptic drugs.....	354	3.2. Analytical decreases of sodium.....	396
3.4. Cardiac glycosides, anti-angina drugs, vasodilators, antiarrhythmics.....	356	3.3. No analytical interference.....	396
3.5. Antihistamine drugs, histamine H ₂ -receptor antagonists, beta-blocking agents.....	356	4. PHARMACOLOGICAL EFFECTS.....	396
3.6. Diuretics.....	357	4.1. Diuretics.....	397
3.7. Anti-infectious drugs, anti-malaria drugs, anti-protozoan drugs and anti-virus drugs.....	357	4.1.1. Diuretics acting on the loop of Henle.....	398
3.8. Anticoagulants.....	358	4.1.2. Thiazide diuretics.....	399
3.9. Oral contraceptives.....	358	4.1.3. Inhibitors of ionic exchanges in the distal tubule.....	399
3.10. Anti-gout agents.....	359	4.1.4. Osmotic diuretics.....	400
3.11. Androgen hormones.....	359	4.2. Antihypertensive drugs.....	400
3.12. Hypnotic agents, tranquillizers.....	360	4.3. Cardiotonic agents.....	401
3.13. Lipid-lowering drugs.....	360	4.4. Beta-blocking agents.....	401
3.14. Cytostatic drugs.....	360	4.5. Antiepileptic drugs.....	401
4. CONCLUSION.....	361	4.6. Analgesics and anti-inflammatory drugs.....	402
		4.7. Oral contraceptives.....	402
POTASSIUM.....	362	4.8. Estrogens.....	402
1. METABOLIC BACKGROUND.....	362	4.9. Progestogens.....	402
2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	363	4.10. Anti-gout drugs.....	402
3. ANALYTICAL INTERFERENCES.....	366	4.11. Bronchodilator drugs.....	402
3.1. Analytical increases of potassium.....	367	4.12. Cardiac analeptic drugs.....	402
3.2. Analytical decreases of potassium.....	367	4.13. Vitamins.....	403
3.3. No analytical interference.....	367	4.14. Sugars.....	403
4. PHARMACOLOGICAL EFFECTS.....	368	4.15. Miscellaneous.....	403
4.1. Diuretics.....	368		
4.2. Beta-blockers.....	371	TRIGLYCERIDES.....	405
4.3. Antihypertensive agents.....	371	1. METABOLIC BACKGROUND.....	405
4.4. Cardiotonic agents.....	371	2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	406
4.5. Analeptic drugs.....	372	3. ANALYTICAL INTERFERENCES.....	408
4.6. Antiepileptic drugs.....	372	3.1. A summary of the main methods of quantifying triglycerides.....	408
4.7. Estrogens.....	372	3.2. Interference by free glycerol.....	408
4.8. Progestogens.....	372	3.3. Interferences by drugs.....	408
4.9. Oral contraceptives.....	372	4. PHARMACOLOGICAL EFFECTS.....	415
		4.1. Lipid-lowering drugs.....	415

4.2. Hypoglycemic agents.....	417
4.3. Antihypertensive drugs.....	417
4.4. Oral contraceptives.....	419
4.5. Antiepileptic drugs.....	422
4.6. Miscellaneous.....	422

URATES..... 423

1. METABOLIC BACKGROUND.....	423
2. REFERENCE LIMITS, AND PREANALYTICAL, PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	423
3. ANALYTICAL INTERFERENCES.....	426
3.1. Sources of interferences in the phosphotungstic acid reduction method.....	426
3.2. Sources of interferences in other chemical methods.....	432
3.3. Sources of interferences in enzymatic methods.....	432
3.4. Analytical interferences in high-performance liquid chromatography.....	434
4. PHARMACOLOGICAL EFFECTS.....	435
4.1. Increase in blood urate concentrations.....	436
4.1.1. Diuretics.....	436
4.1.2. Drugs used to treat tuberculosis.....	436
4.1.3. Anti-cancer agents.....	436
4.1.4. Drugs acting on the cardiovascular system.....	436
4.2. Drugs that lower blood urate concentrations.....	437
4.2.1. Uricosurics.....	437
4.2.2. Xanthine oxidase inhibitors.....	437
4.2.3. Ascorbic acid.....	437
4.2.4. Acetylsalicylic acid.....	437
4.2.5. Diuretics.....	438

UREA..... 439

1. METABOLIC BACKGROUND.....	439
2. REFERENCE LIMITS, AND PHYSIOLOGICAL, AND PATHOLOGICAL VARIATIONS.....	440
3. ANALYTICAL METHODS.....	442
3.1. Diacetylmonoxime methods.....	442
3.2. Urease methods.....	442
3.2.1. Nessler reaction.....	442
3.2.2. Berthelot reaction.....	442
3.2.3. Totally enzymatic method.....	443
3.3. Method using paradimethylaminobenzaldehyde.....	443
3.4. Method using o-phthalaldehyde-methoxyquinoline.....	443
4. ANALYTICAL INTERFERENCES.....	444
4.1. The main sources of analytical interferences.....	444
4.1.1. With the diacetylmonoxime method.....	444
4.1.2. With the urease method.....	444
4.1.3. With the method using paradimethylaminobenzaldehyde.....	444
4.1.4. With the method using o-phthalaldehyde-methoxyquinoline.....	444
4.2. No analytical interference.....	445
5. PHARMACOLOGICAL EFFECTS.....	450
5.1. Decreases of blood urea.....	450
5.2. Increases of blood urea.....	451
5.2.1. In hypertensive subjects.....	451
5.2.2. In subjects with cancer or leukemia.....	452
5.2.3. In other subjects.....	452

**CONSTRUCTION OF THE INTERMEDIC DATABASE:
PHYSIOLOGICAL VARIATIONS AND EFFECTS OF DRUGS ON
LABORATORY TESTS..... 454**

FOREWORD

J. Frei

The directors and staff of clinical chemistry laboratories, as well as physicians, are confronted daily with a problem of whose consequences they are largely unaware: the interference of drugs with many constituents of blood and urine. In recognition of the importance of the problem, the International Federation of Clinical Chemistry created the Expert Panel on Drug Effects in Clinical Chemistry, of which Professor Gérard Siest is appointed chairman. The first major work in this field was D.S. Young's computerized list (Clin. Chem., 1972, 18, 1041-1303), and other publications have followed. However the topic is so important and our knowledge has progressed so steadily, that the present contribution, by Professor Siest and his co-workers at the Center for Preventive Medicine in Vandoeuvre-les-Nancy, France, is particularly welcome. The authors wish to heighten the awareness of clinical chemists and at the same time to offer them a reference work. Their approach is novel, including much of their own work. They have sought to help the reader to understand a difficult and often confused field, by means of a scientific, didactic, and pragmatic approach. They have taken into consideration the latest publications, and have drawn on their wide experience gained over many years at the Center for Preventive Medicine and in a specialist working group of the European Economic Community. The original version was published in French but considering the importance of the matter the authors estimated necessary to publish an English version which was reviewed by Dr D.S. Young, a specialist in the field of drug interferences. The group at Vandoeuvre has created a data bank concerning drug interferences, which is descri-

bed in the last chapter: the data bank is also accessible through the "Minitel" system of the "Société Française de Biologie Clinique".

More than twenty chapters of this book are devoted to the analytical (in vitro) and pharmacological (biological; in vivo) effects of drugs on the concentrations of the most commonly estimated biochemical constituents (metabolites, electrolytes, enzymes, etc.) and on some hematological parameters. The authors also review physiological and pathological aspects of each constituent, the reference intervals for each, and the preanalytical factors that can affect the results.

The drug effects discussed in the book are part of the vast background of factors that can interfere with clinical laboratory investigation of patients. Unforeseen and often serious consequences may follow if these factors are poorly understood, or ignored. Thus this book is recommended to those who provide and those who use clinical laboratory results, as well as to teachers of clinical chemistry and medicine.

LABORATORY TESTS AND DRUGS

G. Siest

The administration of drug(s) to humans (or to animals) can alter laboratory tests, which are widely used to monitor the effects of taking these very drug(s) (300). We have developed different approaches to study the undesirable effects and the optimal use of laboratory tests:

(i) drugs or their metabolites can affect laboratory tests by either analytical or pharmacological means. This problem must be placed in its proper perspective. And conversely,

(ii) laboratory tests are widely used to assess toxicity of drugs in animals, and then during clinical trials in humans; and they are also used to monitor therapy.

The interpretation of laboratory test values in the presence of drugs will be different in these two situations. Drugs must be included among the variables affecting laboratory tests. They are factors which must be understood so that their effects may be eliminated or controlled.

1. EFFECTS OF DRUGS ON LABORATORY TESTS

A drug taken before the collection of a blood specimen can induce an increase or a decrease in the concentration of a plasma constituent. This effect can arise in two ways (750). One is purely analytical: the drug and/or its metabolites may at any stage affect the measurement of a constituent. In laboratory medicine this is called "analytical interference".

The second means is biological: the drug induces a change in a biological parameter by a physiological, pharmacological, or toxicological mechanism. This constitutes what is customarily called the

effects of a drug on laboratory tests (744). This very general (too general) term therefore encompasses the unexpected secondary effects, desirable or undesirable, of drugs. It also sometimes includes the results of drug interactions, a term which has been proposed but which should be restricted to pharmacology.

These effects may remain unnoticed, since laboratory tests are often ordered without knowledge of the drugs being taken by a person. Yet laboratory procedures may be used to investigate the liver, the kidney, or the phosphorus/calcium metabolism of a patient who is undergoing unrelated treatment with tranquilizing, hypnotic, or contraceptive drugs. This is one more reason to make a great effort to educate clinicians and clinical chemists. Of the factors that cause variation in laboratory test values, drugs are thought to be as important as age or excess weight (754, 755, 758).

For more than 10 years three organizations have considered this problem:

First of all, in 1974 the European Economic Community set up a working group on "Drug Interference in Clinical Chemistry", which produced a report (738) and general recommendations. (The members were: G. Siest, W. Appel, G.B. Blijenberg, B. Capolaghi, M.M. Galteau, C. Heughem, M. Hjelm, K.L. Lauer, B. Le Perron, V. Loppinet, C. Love, R.J. Royer, G. Tognoni, and P. Wilding.).

On the boarder topic of the effects of drugs, including both analytical interference and pharmacological variations as undesirable effects, and on the other hand as a means of following and monitoring drugs, International Federation of Clinical Chemistry (IFCC) set up a group of experts (Expert Panel on "Drug Effects in Clinical Chemistry": G. Siest (Chairman), P.A.G. Malya, J.G. Salway, F.W. Sunderman, G. Tognoni, and N. Tryding), and the Société Française de Biologie Clinique (SFBC) (French Society of Clinical Chemistry) established a French-speaking commission (on "Effets des médicaments sur les examens de laboratoire") (Drug Effects on Laboratory Tests), comprising: G. Siest (Chairman), M. Azria, A. Cloarec, J. Delattre, A. Galli, M.M. Galteau, D. Gouy, J.F. Guelfi, P. Jouanel,

J. Migne, J. Nachbaur, M. Sergeant, F. Trivin, M. Cortes, P. Delwaide, and R. Galimany; with, as corresponding members, C. Bachmann, J. Breuer, M. Dobrescu, J.G. Salway, T. Spiro, F.W. Sunderman, G. Tognoni, and N. Tryding.

The SFBC has published, or will publish, the following documents:

- . Document A, Notions générales concernant l'effet des médicaments sur les examens de laboratoire (**General concepts concerning the effects of drugs on laboratory tests**), Ann. Biol. Clin., 1981, 39, 91-98
- . Document B, Lignes directrices pour l'étude et la définition d'une interférence analytique. Proposition d'un protocole (**Guidelines for the study and definition of analytical interference: Proposed protocol**), Ann. Biol. Clin., 1984, 42, 137-144
- . Document C, Lignes directrices pour la mise en évidence des effets biologiques des médicaments sur les examens de laboratoire (**Guidelines for the demonstration of biological effects of drugs on laboratory tests**), Inform. Scient. Biol., 1984, 10, 160-163
- . Document D, Les examens de laboratoire au cours des études de toxicologie sur animaux de laboratoire (**Laboratory tests during toxicity studies on laboratory animals**), Inform. Scient. Biol., 1984, 10, 403-406
- . Document E, Les examens de laboratoire au cours des essais cliniques chez l'homme (**Laboratory tests during clinical trials in humans**), Inform. Scient. Biol., 1985, 11, 52-55
- . Document F, Utilisation des examens de laboratoire pour la surveillance thérapeutique (**Use of laboratory tests to monitor therapy**), Inform. Scient. Biol., 1985, 11, 99-106
- . Document G, Banques de données (**Data banks**), Ann. Biol. Clin., sous presse.

The International Federation of Clinical Chemistry has published or will publish the following documents:

- . Part 1, The basic concepts, J. Clin. Chem. Clin. Biochem., 1984, 22, 271-274 and Clin. Chim. Acta, 1984, 139, 215F-221F

- . Part 2, Guidelines for evaluation of analytical interference, J. Clin. Chem. Clin. Biochem., 1984, 22, 275-279 and Clin. Chim. Acta, 1984, 139, 223F-230F
- . Part 3, Evaluation of biological effects of drugs, submitted in J. Clin. Chem. Clin. Biochem.
- . Part 4, Clinical laboratory tests on laboratory animals during toxicity studies, submitted in J. Clin. Chem. Clin. Biochem.
- . Part 5, Laboratory tests during clinical trials, submitted in J. Clin. Chem. Clin. Biochem.
- . Part 6, Laboratory tests in monitoring drug administration, submitted in J. Clin. Chem. Clin. Biochem.
- . Part 7, Data banks, submitted in J. Clin. Chem. Clin. Biochem.

1.1. Analytical interference

Analytical interference constitutes part of the total effects, but represents only about 20 % of the cases in the list drawn up by Young et al. (929). It may be due either to the drug itself or to its metabolites. The effect may be because the interfering substance has a structure similar to that of the compound being estimated; thus, methyldopa is included in the measurement of total catecholamines. Alternatively the interfering substance may affect spectrophotometric reactions: (a) it may yield a similar color as with salicylates which react the same way with Folin's reagent as do urates (or may produce a different color); or (b) it may have its own fluorescence or, more often, may inhibit another compound's fluorescence (quenching); or (c) it may cause turbidity or a precipitate. This latter type of interference is common when the reactions take place in very acid or very alkaline media.

Interference may also be due to the chemical properties of the drugs present, but this type appears in general only at high concentrations. The reducing power of the drugs and/or of their metabolites is often the main factor; thus, ascorbic acid interferes with many determinations because of its pronounced reducing properties.